一种新型宫颈癌靶向治疗系统：MDC1 反义长链非编码 RNA 与奥沙利铂磁性热敏阳离子脂质体药物载体的共递送系统。
A Novel Targeted Therapy System for Cervical Cancer: Co-Delivery System of Antisense LncRNA of MDC1 and Oxaliplatin Magnetic Thermosensitive Cationic Liposome Drug Carrier.
机构信息
School of Basic Medical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, 325035, People's Republic of China.
School of Stomatology, Wenzhou Medical University, Wenzhou, Zhejiang, 325035, People's Republic of China.
出版信息
Int J Nanomedicine. 2021 Feb 11;16:1051-1066. doi: 10.2147/IJN.S258316. eCollection 2021.
BACKGROUND
This study was aimed to prepare a novel magnetic thermosensitive cationic liposome drug carrier for the codelivery of Oxaliplatin (OXA) and antisense lncRNA of MDC1 (MDC1-AS) to Cervical cancer cells and evaluate the efficiency of this drug carrier and its antitumor effects on Cervical cancer.
METHODS
Thermosensitive magnetic cationic liposomes were prepared using thin-film hydration method. The OXA and MDC1-AS vectors were loaded into the codelivery system, and the in vitro OXA thermosensitive release activity, efficiency of MDC1-AS regulating MDC1, in vitro cytotoxicity, and in vivo antitumor activity were determined.
RESULTS
The codelivery system had desirable targeted delivery efficacy, OXA thermosensitive release, and MDC1-AS regulating MDC1. Codelivery of OXA and MDC1-AS enhanced the inhibition of cervical cancer cell growth in vitro and in vivo, compared with single drug delivery.
CONCLUSION
The novel codelivery of OXA and MDC1-AS magnetic thermosensitive cationic liposome drug carrier can be applied in the combined chemotherapy and gene therapy for cervical cancer.
背景
本研究旨在制备一种新型的磁性热敏阳离子脂质体药物载体，用于奥沙利铂（OXA）和反义 lncRNA 的 MDC1（MDC1-AS）共递送到宫颈癌细胞，并评估这种药物载体的效率及其对宫颈癌的抗肿瘤作用。
方法
采用薄膜水化法制备热敏磁性阳离子脂质体。将 OXA 和 MDC1-AS 载体载入共递药系统，并测定其体外 OXA 热敏释放活性、MDC1-AS 调节 MDC1 的效率、体外细胞毒性和体内抗肿瘤活性。
结果
共递药系统具有良好的靶向递药效果、OXA 热敏释放和 MDC1-AS 调节 MDC1。与单药给药相比，共递 OXA 和 MDC1-AS 增强了体外和体内对宫颈癌细胞生长的抑制作用。
结论
新型 OXA 和 MDC1-AS 磁性热敏阳离子脂质体共递药载体可应用于宫颈癌的联合化疗和基因治疗。
Zotero 插件